Nicotine
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Nicotine
Nicotine: Known uses and market status in Australia
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Nicotine, so there is currently no new predicted indication. The uses recorded for this drug are listed below.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 3 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| beriberi |
| nicotine dependence |
| pellagra |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 10076H | nicorette 16hr Invisipatch | Transdermal patch 39.4 mg | Valid |
Safety Considerations
Product-label warnings and contraindications were not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for safety information.
Knowledge-graph contraindication signals (not label text): The knowledge graph links nicotine with contraindication to the following conditions, which should be verified against the PI:
- Cardiovascular: acute coronary syndrome, coronary artery disease, myocardial infarction, coronary thrombosis, Prinzmetal angina, hypotensive disorder
- Endocrine and metabolic: diabetes mellitus (including type 1), diabetic ketoacidosis, hyperglycaemia, hyperthyroidism (Graves disease, thyrotoxicosis), phaeochromocytoma, gout
- Gastrointestinal and hepatic: peptic ulcer disease, liver disease, gallbladder disease
- Haematological: thrombocytopenia, blood coagulation disease, haemoglobinopathy
- Other: substance abuse/dependence, and several cancers (duodenum, small intestine, heart, adrenal gland, sympathetic paraganglioma)
Drug interactions: 100 interactions were identified in total; the first 20 are listed in the data compiled for this report. The main ones with a defined severity are:
- Moderate: bupropion
- Minor: famotidine, ranitidine (including ranitidine bismuth citrate), cimetidine, nizatidine
Other listed interactions (for example pantoprazole, omeprazole, lansoprazole, metformin, glimepiride, rosiglitazone, morphine, prednisone) have an unknown severity rating.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.